Repatha® is indicated:
*Based on the proportion of patients with ASCVD at very high risk for a cardiovascular event using IQVIA LAAD claims data and patient data linked between Quest Diagnostics and IQVIA from January 2018 to December 2022 in the United States.2
†Covered includes Covered, Covered (PA/ST), Preferred, and Preferred (PA/ST) as defined by Managed Markets Insights and Technology (MMIT) data. Number of commercially insured lives provided is obtained from MMIT for commercial health plans in the United States as of August 2024. Inclusion on formulary does not imply superior clinical efficacy or safety.
‡Eligibility criteria and program maximums apply. Please see full Terms and Conditions at Repatha.com/copaytcs.
§Cumulative post-market exposure estimates from July 2015 through May 2024, on patients that have received at least 1 dose administration of the product. The number of patients receiving at least 1 administration is estimated using worldwide unit sales data, prescription claims data, and applying utilization assumptions to calculate the unique number of patients. Sources include Amgen Finance Electronic Data Warehouse, IQVIA prescription claims, and MarketScan claims data. The estimates assume patient self-administration, based on filled prescriptions.
IQVIA, IMS Quintiles Virtual Information Access; LAAD, longitudinal access and adjudication data.